Idorsia In Dreamland With Insomnia Drug Approval

FDA Green Light For Daridorexant

The Swiss biotech has got the thumbs up in the US for its insomnia drug which will be sold as Quviviq and is expected to be provide serious competition for Merck & Co's rival dual orexin receptor antagonist Belsomra.

Idorsia building
• Source: Idorsia

Shares in Idorsia Pharmaceuticals Ltd are on the rise after the Swiss biotech received US approval for daridorexant, its closely watched sleeping pill which has been shown to help users function normally the next day.

The US Food and Drug Administration has approved 25mg and 50mg doses of daridoxerant, which will be marketed under the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip